Abstract
Optimal prevention of transfusion-transmitted cytomegalovirus (TTCMV) infection by modern leukocyte reduction alone: CMV sero/antibody-negative donors needed only for leukocyte products.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have